A MULTICENTER PHASE 2B RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED DOSE-RANGING STUDY OF TOUR006 IN PARTICIPANTS WITH THYROID EYE DISEASE

Registry ID

TOUR006-T01

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

TOURMALINE BIO, INC.

Start date

2025-01-07

Last update

2023-10-26

Conditions

• THYROID EYE DISEASE

Related clinical trials

• A PHASE 1/2, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF AMG 732 IN HEALTHY SUBJECTS AND SUBJECTS WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
• A PHASE 3, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF EFGARTIGIMOD PH20 SC ADMINISTERED BY PREFILLED SYRINGE IN ADULT PARTICIPANTS WITH THYROID EYE DISEASE
• A PHASE 3, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF SUBCUTANEOUS TEPROTUMUMAB IN PARTICIPANTS WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
• A PHASE III, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PARTICIPANTS WITH MODERATE-TO-SEVERE THYROID EYE DISEASE
• A PHASE 2B, RANDOMIZED, DOUBLE-MASK, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF LINSITINIB IN SUBJECTS WITH ACTIVE, MODERATE TO SEVERE THYROID EYE DISEASE (TED)
• A MULTIPLE ASCENDING DOSE (MAD) SAFETY, TOLERABILITY AND EFFICACY STUDY OF VRDN-001, A HUMANIZED MONOCLONAL ANTIBODY DIRECTED AGAINST THE IGF-1 RECEPTOR, IN NORMAL HEALTHY VOLUNTEERS (NHVS) AND SUBJECTS WITH THYROID EYE DISEASE (TED)

View on source registry